Melorheostosis: a Rare Sclerosing Bone Dysplasia
- 751 Downloads
Purpose of Review
Melorheostosis is a rare sclerosing bone dysplasia that affects both cortical bone and adjacent soft tissue structures in a sclerotomal distribution. In this review, we describe the natural history, radiological features, proposed pathogenesis, and management options for this debilitating condition.
Since its first description in 1922, about 400 cases of melorheostosis have been reported, either as single reports or in small case series. Melorheostosis affects the appendicular skeleton more commonly than the axial skeleton and usually presents with lower limb deformity. Diagnosis is based on a combination of clinical and radiological features that help differentiate this condition from other sclerosing bone dysplasias. LEM domain-containing protein 3 (LEMD3) gene mutations have been demonstrated in several familial cases, but these have been more strongly correlated with other hereditary dysplasias, such as osteopoikilosis, and are not thought to be the causative gene for melorheostosis. The exact etiology of classic sporadically occurring melorheostosis remains unknown, with possible causes being somatic LEMD3 mutations, somatic mutations in the bone morphogenetic protein/transforming growth factor-beta pathway, mutations in multiple genes, or other non-genetic causes. Management in recent years has involved nitrogen-containing bisphosphonates in addition to traditional orthopedic surgical approaches and physical therapy.
Melorheostosis may present as mixed or atypical osseous involvement in addition to the classically described “dripping candle wax” appearance of hyperostosis. Some patients may have overlap with osteopoikilosis or Buschke–Ollendorff syndrome. In the future, better characterization of genetic and developmental factors predisposing to melorheostosis may lead to the development of targeted therapy for this condition, as well as for more commonly encountered skeletal abnormalities.
KeywordsMelorheostosis Hyperostosis Bone dysplasia Sclerotomal distribution
Compliance with Ethical Standards
Conflict of Interest
Bart Clarke and Anupam Kotwal declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 2.Léri A, Joanny J. Une affection non décrite des os: hyperostose “en coulée” sur toute la longueur d’un membre ou “mélorhéostose”. Bull Mem Soc Med Hosp Paris. 1922;46:1141–5Google Scholar
- 10.• Smith GC, Pingree MJ, Freeman LA, Matsumoto JM, Howe BM, Kannas SN, et al. Melorheostosis: A retrospective clinical analysis of 24 patients at the Mayo Clinic. PM&R. 2016;30:30813–9. This is the largest available case series reporting that the most common radiological finding in melorheostosis patients is a mixed pattern consisting of different forms of hyperostosis.Google Scholar
- 13.• Ihde LL, Forrester DM, Gottsegen CJ, Masih S, Patel DB, Vachon LA, et al. Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. RadioGraphics. 2011;31:1865–82. This review describes the various sclerosing bone dysplasias, differentiating between hereditary and non-hereditary conditions, and discusses each condition briefly.CrossRefGoogle Scholar
- 25.Kim JE, Kim EH, Han EH, Park RW, Park IH, Jun SH, et al. A TGF-beta-inducible cell adhesion molecule, betaig-h3, is downregulated in melorheostosis and involved in osteogenesis. J Cell Biochem. 2000;77:169–78Google Scholar
- 27.Jha S, Papadakis G, Kim L, Malayeri A, Cowen EW, Lehky T, et al. Melorheostosis: clinical experience of 23 cases. Endocrine Society 2017. Orlando, FL. 2017. AbstractGoogle Scholar
- 33.Slimani S, Nezzar A, Makhloufi H. Successful treatment of pain in melorheostosis with zoledronate, with improvement on bone scintigraphy. BMJ Case Rep. 2013; 2013:pii: bcr2013009820Google Scholar